HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Viral hepatitis: global goals for vaccination.

Abstract
In countries where hepatitis A is highly endemic, exposure to hepatitis A virus (HAV) is almost universal before the age of 10 years, and large-scale immunization efforts are not required. In contrast, in areas of intermediate endemicity or in transition from high to intermediate endemicity, where transmission occurs primarily from person to person in the general community (often with periodic outbreaks), control of hepatitis A may be achieved through widespread vaccination programmes. Hepatitis B virus (HBV) is one of the world's most widespread infectious agents and the cause of millions of infections each year. Between 500,000 and 700,000 people die each year from chronic infection-related cirrhosis, hepatocellular carcinoma (HCC) or from acute hepatitis B. Hepatitis B vaccine provides protection against infection and its complications including liver cirrhosis and HCC. It is therefore, the first vaccine against a cancer, the first vaccine protecting from a sexually transmitted infection, and the first vaccine against a chronic disease ever licensed. Control and significant reduction in incidence of new HBV infections as well as hepatocellular carcinoma has repeatedly been reported in countries in East Asia (i.e. Taiwan) and Africa (i.e. The Gambia). Two experimental vaccines against hepatitis E have been developed; one of them has been recently licensed but is not yet widely available. Attempts to develop a hepatitis C vaccine were so far unsuccessful.
AuthorsDaniel Lavanchy
JournalJournal of clinical virology : the official publication of the Pan American Society for Clinical Virology (J Clin Virol) Vol. 55 Issue 4 Pg. 296-302 (Dec 2012) ISSN: 1873-5967 [Electronic] Netherlands
PMID22999800 (Publication Type: Journal Article, Review)
CopyrightCopyright © 2012 Elsevier B.V. All rights reserved.
Chemical References
  • Viral Hepatitis Vaccines
Topics
  • Biomedical Research (trends)
  • Drug Discovery (trends)
  • Global Health
  • Hepacivirus (immunology)
  • Hepatitis A virus (immunology)
  • Hepatitis B virus (immunology)
  • Hepatitis E virus (immunology)
  • Hepatitis, Viral, Human (epidemiology, prevention & control, virology)
  • Humans
  • Vaccination (statistics & numerical data)
  • Viral Hepatitis Vaccines (administration & dosage, immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: